preamble
Daring to seek change, we are brave to be a breaker; brave to seek new, we strive to be a pioneer; good at seeking quality, we should be an enabler; happy to seek progress, we are tight to be an aggregator.
The use of animal cell bioreactors to produce gene therapy, cell therapy, and vaccines and antibody drugs is an important part of the modern biomedical industry, and the role of these products in disease control and treatment of major diseases is irreplaceable. With the deepening of Made in China 2025, in order to accelerate the product upgrading and innovation of Voltis Biologics in the field of domestic high-end animal cell bioreactor equipment, Voltis Biologics joins hands with the State Key Laboratory of Bioreactors of East China University of Science and Technology, the two sides have strong cooperation and complement each other's strengths, and jointly create the "Voltis Biologics" on the basis of the transfer of technological innovations, product scientific and technological innovations, and the training of human resources. East China University of Science and Technology-Votis Bioreactor Process Control and Intelligent Manufacturing Joint Technology Innovation Transfer Center". The office address of the Innovation Center is located in East China University of Science and Technology, with Prof. Yingping Zhuang, former Dean of the School of Bioengineering of East China University of Science and Technology, as the President, and Xiaoping Yi (East China University of Science and Technology) as the Vice-President, who is in charge of the specific day-to-day operation of the Innovation Center.
The Technology Innovation Center will give full play to the leading technological advantages of the State Key Laboratory of Reactors in process control and intelligent manufacturing of animal cell reactors, focusing on lab-scale to super-large production-scale bioreactors of more than 20,000 liters, and ploughing deeply into the key technologies of digital transformation of the modern biomedical industry: intelligent sensing, intelligent analysis, intelligent optimization, and intelligent execution, so as to form an integrated technological system of animal cell bioreactors with the integration of intelligent sensing, intelligent diagnostics, and intelligent control technologies, and to be the forerunner and pioneer in the digital transformation of the biomedical industry and intelligent manufacturing in China.
About Voltis
Founded in 2022, Votis (Nantong) Biotechnology Co., Ltd. is a high-end bioreactor research, development, production and sales biotechnology company, which is held by its parent company, Suzhou Womei Biologicals Co., Ltd. and jointly established with listed company, Zhi Chun Science and Technology Group (stock code: 603690), a wholly-owned subsidiary of EnChem Pharmaceutical Systems Engineering (Shanghai) Co.
Strong alliance empowers development
Womei Bio
Suzhou Womei Biology CO,.Ltd is a leading one-stop solution provider for biopharmaceuticals in China. Its main products include upstream and downstream core suppliers of bioprocesses, such as personalized media, bioreactors, immunoadjuvants, and biological reagents, as well as providing formulation and production, process optimization, process validation, technical support, and ancillary services for the biopharmaceutical industry.
East China University of Science and Technology
East China University of Science and Technology is a well-known double first-class university, the State Key Laboratory of Bioreactor Engineering was built in 1996, since the establishment of the State Key Laboratory, the achievements have been outstanding, won the second prize of the National Scientific and Technological Progress 2, the provincial and ministerial level scientific and technological progress award 10. It has published nearly 100 papers in international SCI-indexed journals and widely cited by international peers, 250 academic papers in domestic core journals, 12 monographs in English and Chinese, 5 national invention patents authorized, more than 10 public, and 20 provincial and ministerial appraisal results. The State Key Laboratory of Reactor has made outstanding progress in the creation of bioreactors, optimization and amplification of biological processes and other applied basic research, and innovatively put forward the optimization and regulation strategies and means of biological processes, as well as the creation of related hardware and software, which has achieved great economic and social benefits.
Enamel Haoxin
As a wholly owned subsidiary of Shanghai Zhi Pure Clean System Technology Co., Ltd (Stock Code: 603690), Enclave Haoxin is committed to providing professional clean fluid system engineering services for the biopharmaceutical, daily-use chemical, food and related industries. The core members of the team have more than 20 years of experience in fluid engineering design and implementation, including technical consulting, design, manufacturing and project management. Currently, we have industry-leading implementation experience and exemplary projects in the fields of large molecule biopharmaceuticals and highly active products, especially monoclonal antibodies, human and animal vaccines, blood products, insulin, cell therapy, gene therapy, etc. We have served more than 100 well-known pharmaceutical companies. We have served more than 100 well-known pharmaceutical companies, including 8 of the world's top 10 pharmaceutical companies as long-term partners.
Technological innovation and quality products
The Technology Innovation Center will focus on the key technology platform for modern biomedical digital transformation and intelligent manufacturing, form a mature product technology and transformation system, empower products, and continuously pursue to provide customers with more innovative and higher quality products and services, provide a constant power for technological innovation and development in the field of high-end bioreactor equipment, and improve strong support for the digital transformation of China's biomedical industry.
